FDA Lifts Clinical Hold on Intellia's Gene Editing Drug, Shares Rise

Intellia Therapeutics shares rose by 15% in the premarket after the FDA lifted a clinical hold on the late-stage trial for its gene editing therapy, nexiguran ziclumeran (nex-z), co-developed with Regeneron. The FDA's decision allows the trial to resume, providing a positive development for Intellia and its partner, Regeneron.